Processa Pharmaceuticals, Inc. — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
In July 2026, Processa acquired Vidya Therapeutics and completed a concurrent private placement raising approximately $200M (net proceeds ~$183.3M) from institutional healthcare investors. The transaction funds operations into H2 2029 and refocuses the company on immunological/inflammatory diseases, with lead program VT-7208 (BTK inhibitor) advancing into Phase 2 trials for food allergy, chronic spontaneous urticaria, and relapsing MS. As-converted share count increases to ~309.3M (from ~2.8M common currently outstanding), requiring stockholder approval to convert ~306.5M Series A preferred shares to common.
Why this rating
For an $8.1M market-cap company, a $183M+ net financing is >22× annual market value—transformational. Acquisition + clinical pipeline + 2.5-year runway materially alters trajectory and survival odds.
Tradability signal
NO TRADE
No trade: only ~$44k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $1.94 | +10 min · unknown $1.83 ▼ 5.43% | +30 min · unknown $1.90 ▼ 1.81% | +1 hr · unknown $1.86 ▼ 3.88% | +4 hrs · unknown $1.85 ▼ 4.39% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.